ProCE Banner Activity

Understanding the FGFR-Targeted Therapy Erdafitinib

Multimedia
Kinjal Patel, PharmD, BCOP, discusses the mechanism of action, indication, and treatment considerations when using erdafitinib for patients with advanced or metastatic urothelial carcinoma.

Released: December 01, 2020

Expiration: November 30, 2021

No longer available for credit.

Share

Faculty

Kinjal Patel

Kinjal Patel, PharmD, BCOP

Clinical Oncology Pharmacist
Department of Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Susan Roethke

Susan Roethke, CRNP, MSN, AOCN, ANP-BC

Nurse Practitioner
Department of Hematology/Oncology
Genitourinary Medical Oncology
Fox Chase Cancer Center
Temple Health
Philadelphia, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Astellas Seattle Genetics

Janssen administered by Scientific Affairs

Learning Objectives

  • Plan therapy for patients with urothelial carcinoma and disease progression during or following platinum-containing chemotherapy and/or immune checkpoint inhibitor therapy
  • Describe to patients and colleagues the available data and unique mechanisms of action of novel targeted therapies for the treatment of advanced urothelial carcinoma
  • Evaluate the toxicity profile as well as the pharmacokinetics and exposure-response association of approved antibody–drug conjugates in urothelial carcinoma

Faculty Disclosure

Primary Author

Kinjal Patel, PharmD, BCOP

Clinical Oncology Pharmacist
Department of Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Kinjal Patel, PharmD, BCOP, has no relevant conflicts of interest to report.

Susan Roethke, CRNP, MSN, AOCN, ANP-BC

Nurse Practitioner
Department of Hematology/Oncology
Genitourinary Medical Oncology
Fox Chase Cancer Center
Temple Health
Philadelphia, Pennsylvania

Susan Roethke, CRNP, MSN, AOCN, ANP-BC has received fees for Non-CME/CE services from Astellas and Pfizer.

Staff Disclosure

Staff

Jason J. Everly, PharmD

Jason J. Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has disclosed that his spouse/partner has received salary from AstraZeneca and has ownership interest in AstraZeneca.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Kristen Rosenthal, PhD

Clinical Editor

Kristen M. Rosenthal, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.